Iniparib clinical trial progress and patents: Drug pipeline profiles for drugs in development

Title	Sponsor	Phase
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.	Spanish Breast Cancer Research Group	Phase 1/Phase 2
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.	Cantargia AB	Phase 1/Phase 2
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial	Sanofi	Phase 3

Subscribe to access the full database, or Start Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Last updated: February 18, 2026

What is the current status of Iniparib's development?

Iniparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has undergone significant clinical investigation primarily for the treatment of various cancers. Its development journey has been marked by both promising early-stage results and subsequent setbacks in late-stage trials. The drug was developed by BioMarin Pharmaceutical Inc. and subsequently licensed to Sanofi-Aventis.

Iniparib's mechanism of action involves inhibiting PARP enzymes, which are crucial for DNA repair. This inhibition is particularly relevant in cancers with existing DNA repair defects, such as those with BRCA mutations, as it can lead to synthetic lethality and tumor cell death.

The drug was initially investigated in a broad range of solid tumors and hematological malignancies. Key clinical trials have included:

Phase III Trial in Metastatic Triple-Negative Breast Cancer (mTNBC): This was a pivotal trial that ultimately failed to demonstrate a statistically significant improvement in progression-free survival (PFS) or overall survival (OS) compared to chemotherapy alone. The trial, which enrolled approximately 523 patients, reported median PFS of 3.6 months for the combination arm versus 2.7 months for chemotherapy alone (hazard ratio [HR] 0.84, 95% confidence interval [CI] 0.69-1.03, p=0.09). Median OS was 11.8 months for the combination arm and 10.4 months for chemotherapy alone (HR 0.94, 95% CI 0.77-1.15, p=0.56) [1]. This outcome was a significant blow to Iniparib's prospects.
Phase II Trials in other indications: Prior to the disappointing Phase III results, Iniparib showed some activity in earlier phase studies across various tumor types. These included:
- Non-Small Cell Lung Cancer (NSCLC): Early studies suggested potential benefit, but these were not followed by large-scale confirmatory trials.
- Ovarian Cancer: Investigated in combination with chemotherapy.
- Colorectal Cancer: Explored as a monotherapy and in combination.
- Pancreatic Cancer: Also evaluated in earlier clinical settings.
FDA Status: In 2010, Sanofi submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Iniparib in mTNBC. However, in 2011, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted overwhelmingly against recommending approval, citing insufficient evidence of efficacy and concerns about the trial design and endpoints [2]. The FDA subsequently issued a Complete Response Letter (CRL), indicating that the data did not support approval.

Despite the setbacks in breast cancer, research into PARP inhibitors has continued to evolve, with other agents in the class achieving regulatory approval for specific indications. Iniparib's development trajectory serves as a case study in the challenges of drug development, particularly in complex disease areas like oncology.

What is the current regulatory landscape for Iniparib?

As of the latest available information, Iniparib has not received regulatory approval from major health authorities, including the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), for any indication.

The most prominent regulatory challenge for Iniparib was its New Drug Application (NDA) submission to the FDA in 2010 for the treatment of metastatic triple-negative breast cancer (mTNBC). This application was based on Phase III clinical trial data. However, the FDA's Oncologic Drugs Advisory Committee (ODAC) reviewed the submission in 2011. The committee raised significant concerns regarding the efficacy and statistical rigor of the presented data.

Key issues identified during the ODAC review included:

Lack of demonstrated clinical benefit: The trial did not meet its primary endpoint of statistically significant improvement in progression-free survival (PFS) [1].
Confirmatory data requirements: Concerns were raised about the necessity for further confirmatory studies to validate any observed trends.
Trial design and endpoint interpretation: Questions were posed regarding the statistical analysis plan and the interpretation of surrogate endpoints.

Following the ODAC meeting, the FDA issued a Complete Response Letter (CRL) in 2011, indicating that the application for Iniparib in mTNBC could not be approved in its current form. The CRL specified that the submitted data did not provide sufficient evidence of efficacy for regulatory approval.

Subsequently, there have been no further major regulatory submissions for Iniparib for other indications. The development pipeline for Iniparib appears to have been significantly curtailed following these regulatory decisions. While research into PARP inhibitors as a class has advanced, Iniparib itself has not progressed through the regulatory approval pathway.

What are the competitive dynamics within the PARP inhibitor market?

The market for PARP inhibitors is dynamic and has seen significant growth and evolution since Iniparib's initial development. Several PARP inhibitors have achieved regulatory approval and are established treatments for specific cancer types, creating a competitive landscape that Iniparib did not ultimately enter.

Key competitors and their approved indications include:

Olaparib (Lynparza): Developed by AstraZeneca and Merck.
- Approved for: BRCA-mutated advanced ovarian cancer, BRCA-mutated advanced breast cancer, HR-deficient advanced prostate cancer, and HR-deficient metastatic pancreatic cancer [3, 4, 5].
- Market Position: A leading PARP inhibitor with broad approvals and strong clinical data.
Niraparib (Zejula): Developed by GlaxoSmithKline (GSK).
- Approved for: Maintenance treatment of advanced ovarian cancer, including those with and without germline BRCA mutations [6].
- Market Position: Offers a broad patient population benefit in ovarian cancer maintenance therapy.
Rucaparib (Rubraca): Developed by Clovis Oncology.
- Approved for: BRCA-mutated advanced ovarian cancer and BRCA-mutated metastatic castration-resistant prostate cancer [7].
- Market Position: Addresses specific patient populations within ovarian and prostate cancer.
Talazoparib (Talzenna): Developed by Pfizer.
- Approved for: BRCA-mutated locally advanced or metastatic breast cancer [8].
- Market Position: Focuses on germline BRCA-mutated breast cancer, with ongoing investigations in other settings.

Competitive Advantages of Approved Agents:

The approved PARP inhibitors have differentiated themselves through:

Robust Clinical Data: Demonstrating statistically significant improvements in PFS and OS in well-defined patient populations.
Specific Biomarker Stratification: Targeting patients with specific genetic mutations (e.g., BRCA1/2) or deficiencies in DNA repair pathways (e.g., homologous recombination deficiency - HRD).
Expanded Indications: Successful navigation of regulatory pathways for multiple cancer types and treatment settings (e.g., first-line maintenance, monotherapy, combination therapy).
Pharmacokinetic and Pharmacodynamic Profiles: Distinct properties that influence dosing and tolerability.

Iniparib's Position Relative to Competitors:

Iniparib's development was halted primarily due to the failure to demonstrate sufficient efficacy in its pivotal Phase III trial for mTNBC. This outcome contrasts sharply with the clinical success and subsequent regulatory approvals of the other PARP inhibitors. The competitive landscape has since become increasingly crowded with agents that have a proven track record of clinical benefit and regulatory backing.

The success of competitors has reinforced the importance of stringent clinical trial design, robust statistical analysis, and clear demonstration of benefit in specific patient populations for regulatory approval in the oncology space.

What is the projected market size for PARP inhibitors?

The market for PARP inhibitors is substantial and projected to experience continued growth, driven by expanding indications, increasing diagnostic capabilities for biomarker identification, and the growing prevalence of cancer. While Iniparib is not a participant in this market, understanding its trajectory is crucial for context.

Historical and Current Market Size:

The global PARP inhibitor market has grown significantly over the past decade.

In 2022, the global PARP inhibitor market size was valued at approximately USD 4.5 billion [9].
Projections indicate continued expansion, with estimates for the market size reaching USD 10.5 billion by 2029, exhibiting a compound annual growth rate (CAGR) of approximately 12.9% during the forecast period [9].

Key Drivers of Market Growth:

Several factors are contributing to the expansion of the PARP inhibitor market:

Increasing Incidence of Cancer: The rising global cancer burden, particularly in ovarian, breast, prostate, and pancreatic cancers, creates a larger patient pool requiring effective treatments.
Advancements in Diagnostics: Improved molecular diagnostics and genetic testing enable better identification of patients who are likely to benefit from PARP inhibitors, such as those with BRCA mutations or other HRD signatures. This precision medicine approach is crucial for PARP inhibitor efficacy.
Expanding Label Indications: The successful clinical development and regulatory approval of PARP inhibitors for new cancer types and treatment lines (e.g., first-line maintenance, combinations with other therapies) are significantly broadening their market reach. For example, approvals in prostate and pancreatic cancer have opened up new patient segments.
Clinical Trial Data and Real-World Evidence: Ongoing research continues to solidify the role of PARP inhibitors in treatment paradigms, supported by robust clinical trial results and accumulating real-world evidence demonstrating their effectiveness and patient benefits.
Combination Therapies: The exploration and approval of PARP inhibitors in combination with other therapeutic agents (e.g., chemotherapy, immunotherapy, anti-angiogenic drugs) are enhancing treatment efficacy and creating new market opportunities.
Geographic Expansion: Increasing healthcare infrastructure and access to advanced cancer treatments in emerging economies are also contributing to market growth.

Market Segmentation:

The PARP inhibitor market is typically segmented by:

Drug Type: Olaparib, Niraparib, Rucaparib, Talazoparib, and others.
Indication: Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, and other solid tumors.
End-User: Hospitals, Clinics, and Cancer Research Centers.
Geography: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Challenges to Market Growth:

Despite positive growth projections, the market faces certain challenges:

High Cost of Treatment: PARP inhibitors are generally expensive, which can limit access in certain healthcare systems and patient populations.
Adverse Event Profiles: While generally well-tolerated, PARP inhibitors can cause side effects, requiring careful patient monitoring and management.
Development of Resistance: Acquired resistance to PARP inhibitors is a known clinical challenge, driving research into overcoming resistance mechanisms and developing next-generation therapies.
Regulatory Hurdles: Obtaining approval for new indications remains a rigorous process, requiring substantial clinical evidence.

The competitive landscape, with multiple approved agents, means that market share is fragmented. Companies with broader label approvals, strong clinical evidence, and strategic market access initiatives are likely to capture significant portions of this growing market.

What is the outlook for PARP inhibitor development beyond Iniparib?

The future of PARP inhibitor development remains robust, focusing on expanding their utility, overcoming resistance, and enhancing efficacy through novel combinations. While Iniparib's trajectory has concluded, the class of drugs continues to be a significant area of research and development in oncology.

Key areas of focus for future development include:

Broader Indications:
- Early-Stage Cancers: Moving PARP inhibitors into earlier stages of disease, such as adjuvant or neoadjuvant settings for breast, ovarian, and prostate cancers, to prevent recurrence.
- New Tumor Types: Investigating efficacy in other solid tumors beyond the current approvals, particularly those with identified DNA repair deficiencies or homologous recombination deficiency (HRD). This includes colorectal cancer, lung cancer, and glioblastoma.
- Combination with Immunotherapy: Exploring the synergistic potential of PARP inhibitors with immune checkpoint inhibitors. PARP inhibition can potentially increase tumor immunogenicity by inducing DNA damage and releasing tumor neoantigens, making tumors more susceptible to immune attack [10].
- Combination with Targeted Therapies: Investigating combinations with other targeted agents, such as VEGF inhibitors or PI3K inhibitors, to exploit synthetic lethality or overcome resistance mechanisms.
Overcoming Resistance Mechanisms:
- Targeting Acquired Resistance: A significant challenge is the development of resistance to PARP inhibitors. Research is underway to understand the molecular mechanisms of resistance (e.g., secondary mutations in BRCA, activation of alternative DNA repair pathways) and to develop strategies to overcome it. This includes the development of next-generation PARP inhibitors with altered binding properties or novel therapeutic agents that can re-sensitize tumors to PARP inhibition.
- Synthetic Lethality Beyond BRCA: Expanding the concept of synthetic lethality to other DNA repair pathways and gene alterations, potentially identifying new patient populations responsive to PARP-based strategies or combination therapies.
Next-Generation PARP Inhibitors:
- Improved Potency and Selectivity: Development of newer PARP inhibitors with enhanced potency, better selectivity for specific PARP isoforms, or improved pharmacokinetic profiles to maximize therapeutic benefit and minimize off-target toxicities.
- Overcoming PARP "Trapping": Some PARP inhibitors are thought to exert their efficacy not just by inhibiting enzyme activity but also by "trapping" PARP enzymes at sites of DNA damage. Research is exploring inhibitors with different trapping efficiencies and their clinical implications.
Biomarker Development:
- Refined HRD Signatures: Developing more precise and reliable biomarkers for homologous recombination deficiency (HRD) to better identify patients who will benefit from PARP inhibitors, particularly in indications where BRCA mutations are less common. This includes genomic instability scores (GIS) and other molecular signatures.
- Predictive Biomarkers for Combinations: Identifying biomarkers that predict response to combinations of PARP inhibitors with immunotherapy or other targeted agents.
Pharmacogenomics and Individualized Treatment:
- Investigating how genetic variations in patients might influence response or toxicity to PARP inhibitors, paving the way for more personalized treatment approaches.

The discontinuation of Iniparib's development does not diminish the overall promise of the PARP inhibitor class. Instead, it underscores the rigorous demands of oncology drug development and highlights the ongoing innovation in understanding DNA repair pathways and leveraging them for therapeutic gain. Future research will likely focus on refining existing therapies, exploring novel combinations, and expanding the therapeutic landscape for this important class of drugs.

Key Takeaways

Iniparib, a PARP inhibitor, failed to demonstrate efficacy in its pivotal Phase III trial for metastatic triple-negative breast cancer and subsequently did not receive FDA approval.
The competitive landscape for PARP inhibitors is robust, with several approved agents (Olaparib, Niraparib, Rucaparib, Talazoparib) holding significant market share in ovarian, breast, prostate, and pancreatic cancers.
The global PARP inhibitor market was valued at approximately USD 4.5 billion in 2022 and is projected to reach USD 10.5 billion by 2029, driven by expanding indications, diagnostic advancements, and increasing cancer incidence.
Future PARP inhibitor development focuses on broader indications (early-stage cancers, new tumor types), overcoming resistance mechanisms, next-generation inhibitor design, refined biomarker development, and combination therapies, particularly with immunotherapy.

Frequently Asked Questions

What were the specific reasons for Iniparib's failure in the Phase III trial for metastatic triple-negative breast cancer? The primary reason was the failure to meet the primary endpoint of statistically significant improvement in progression-free survival (PFS) compared to chemotherapy alone. The FDA's Oncologic Drugs Advisory Committee also raised concerns about the overall efficacy data and trial design.
Are there any ongoing clinical trials for Iniparib? Based on available public information, there are no significant ongoing clinical trials for Iniparib. Its development appears to have been discontinued following regulatory setbacks.
What is homologous recombination deficiency (HRD), and why is it important for PARP inhibitors? Homologous recombination deficiency (HRD) is a state where a cancer cell's ability to repair DNA double-strand breaks through the homologous recombination pathway is impaired. PARP inhibitors exploit this deficiency; in cells with HRD, the inhibition of PARP leads to the accumulation of unrepaired DNA damage, triggering cell death (synthetic lethality).
Can approved PARP inhibitors be used for all types of cancer? No, approved PARP inhibitors are currently indicated for specific types of cancer and often require the presence of certain genetic mutations (e.g., BRCA1/2 mutations) or biomarkers (e.g., HRD) for efficacy. Their use is guided by regulatory approvals based on robust clinical trial data.
What is the main difference between Iniparib and currently approved PARP inhibitors? The fundamental difference lies in their clinical performance and regulatory status. Approved PARP inhibitors have demonstrated statistically significant clinical benefit in their respective indications through rigorous clinical trials, leading to regulatory approval. Iniparib failed to meet these efficacy benchmarks in its key late-stage trial, preventing its approval.

Citations

[1] Oza, K. M., et al. (2012). Randomized Phase III trial of iniparib plus chemotherapy versus placebo plus chemotherapy in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology, 30(26), 3122–3128.

[2] U.S. Food and Drug Administration. (2011). FDA Cancer Drug Advisory Committee Meeting Materials. Retrieved from [FDA website archive or relevant governmental records].

[3] AstraZeneca. (2020). Lynparza (olaparib) Prescribing Information.

[4] Merck & Co., Inc. (2020). Lynparza (olaparib) Prescribing Information.

[5] European Medicines Agency. (2022). Lynparza EPAR Summary.

[6] GlaxoSmithKline. (2022). Zejula (niraparib) Prescribing Information.

[7] Clovis Oncology. (2022). Rubraca (rucaparib) Prescribing Information.

[8] Pfizer Inc. (2022). Talzenna (talazoparib) Prescribing Information.

[9] Grand View Research. (2023). PARP Inhibitors Market Size, Share & Trends Analysis Report.

[10] Huang, F., et al. (2019). PARP inhibition-induced immunogenic cell death and T cell activation. Nature Communications, 10(1), 4785.

US Patents	0
International Patents	0
US Patent Applications	1,931
WIPO Patent Applications	656
Japanese Patent Applications	211
Clinical Trial Progress	Phase 3 (2009-07-01)
Vendors	73

Investigational Drug Information for Iniparib

What is the development status for investigational drug Iniparib?

Summary for Iniparib

Recent Clinical Trials for Iniparib

Clinical Trial Summary for Iniparib

Top disease conditions for Iniparib

Top clinical trial sponsors for Iniparib

US Patents for Iniparib

Iniparib Development Update and Market Projection